Notice of Proposed Sale · 144
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
JAZZNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
- Issuer CIK
- 0001232524
- SEC file number
- 001-33500
- Phone
- 011-353-1-634-7800
- Person for whose account securities are to be sold
- ROBERT IANNONE
- Relationships to issuer
- Officer
- Street
- Fifth Floor, Waterloo Exchange
- Street (continued)
- Waterloo Road
- City
- Dublin 4
- State / country code
- L2
- Postal code
- D04 E5W7
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 76,921 | 19,207,099.95 | 64,914,577 | 08/27/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/28/2025 | Employee Stock Purchase Plan | ISSUER | 71 | N | 11/28/2025 | Cash |
| Common | 01/16/2026 | Performance Shares | ISSUER | 7,559 | N | 01/16/2026 | Not Applicable |
| Common | 08/27/2026 | Stock Option Exercise | ISSUER | 55,788 | N | 08/27/2026 | Cash |
| Common | 03/05/2026 | Restricted Stock | ISSUER | 13,503 | N | 03/05/2026 | Not Applicable |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted stock during the period of 3/05/2026 through 6/30/2026.
Notice signature
- Notice date
- 08/27/2026
- Signed
- /s/ Robert Iannone
- Plan adoption dates
- 05/28/2026
Company context
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.